Interventional Oncology Devices | US | 2016 | Market Analysis
The US market for interventional oncology devices is growing rapidly, driven by continual device improvement and the adoption of new, innovative products.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the US across a 10-year period.
Ablation therapy for bone and pancreatic cancer represent growth opportunities in the interventional oncology market
Which devices are indicated for these treatments, and how is device approval affecting adoption?
What ablation technologies are being used off-label in these indications?
Microwave ablation devices are growing in popularity among interventional oncologists, and newer technologies, such as IRE, are also being adopted rapidly
What are the advantages and disadvantages of each type of ablation device?
How does the uptake of microwave ablation and IRE devices affect other types of ablation devices?
In which indications will these newer ablation devices experience the fastest adoption?
How can companies in the fragmented microwave ablation market gain a competitive advantage?
Radioembolization beads continue to represent the largest segment of the embolization market, although microspheres and DEBs will experience strong growth over the forecast
What factors (such as the recent SIRFLOX trial) will contribute to the adoption of different embolics for the treatment of both primary and secondary liver cancer?
